Suppr超能文献

地西他滨对人肿瘤中内吞调节因子 RhoA、叶酸载体 RFC1 和 FOLR1 以及葡萄糖转运蛋白 GLUT4 的影响。

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors.

机构信息

Head, Division of Medical Oncology, The Ottawa Hospital/University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8 L6, Canada.

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

出版信息

Clin Epigenetics. 2014 Jan 9;6(1):2. doi: 10.1186/1868-7083-6-2.

Abstract

BACKGROUND

In 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of various membrane transporters. Resistance to chemotherapy may arise due to promoter methylation/downregulation of expression of transporters required for drug uptake, and decitabine can reverse resistance in vitro. The endocytosis regulator RhoA, the folate carriers FOLR1 and RFC1, and the glucose transporter GLUT4 were assessed.

RESULTS

Pre-decitabine RhoA was higher in patients who had received their last therapy >3 months previously than in patients with more recent prior therapy (P = 0.02), and varied inversely with global DNA methylation as assessed by LINE1 methylation (r = -0.58, P = 0.006). Tumor RhoA scores increased with decitabine (P = 0.03), and RFC1 also increased in patients with pre-decitabine scores ≤150 (P = 0.004). Change in LINE1 methylation with decitabine did not correlate significantly with change in IHC scores for any transporter assessed. We also assessed methylation of the RFC1 gene (alias SLC19A1). SLC19A1 methylation correlated with tumor LINE1 methylation (r = 0.45, P = 0.02). There was a small (statistically insignificant) decrease in SLC19A1 methylation with decitabine, and there was a trend towards change in SLC19A1 methylation with decitabine correlating with change in LINE1 methylation (r = 0.47, P <0.15). While SLC19A1 methylation did not correlate with RFC1 scores, there was a trend towards an inverse correlation between change in SLC19A1 methylation and change in RFC1 expression (r = -0.45, P = 0.19).

CONCLUSIONS

In conclusion, after decitabine administration, there was increased expression of some (but not other) transporters that may play a role in chemotherapy uptake. Larger patient numbers will be needed to define the extent to which this increased expression is associated with changes in DNA methylation.

摘要

背景

在 31 名接受去甲基化药物地西他滨治疗的实体瘤患者中,我们在第一个地西他滨周期前后进行了肿瘤活检,并使用免疫组织化学(IHC)评估地西他滨是否增加了各种膜转运蛋白的表达。化疗耐药可能是由于药物摄取所需转运蛋白的启动子甲基化/下调导致的,地西他滨可以在体外逆转耐药。评估了内吞调节因子 RhoA、叶酸载体 FOLR1 和 RFC1 以及葡萄糖转运蛋白 GLUT4。

结果

与最近接受治疗的患者相比,上次治疗超过 3 个月的患者的地西他滨前 RhoA 更高(P=0.02),并且与通过 LINE1 甲基化评估的总体 DNA 甲基化呈负相关(r=-0.58,P=0.006)。肿瘤 RhoA 评分随地西他滨而增加(P=0.03),并且地西他滨前评分≤150 的患者的 RFC1 也增加(P=0.004)。地西他滨治疗后 LINE1 甲基化的变化与评估的任何转运蛋白的 IHC 评分的变化没有显著相关。我们还评估了 RFC1 基因(别名 SLC19A1)的甲基化。SLC19A1 甲基化与肿瘤 LINE1 甲基化相关(r=0.45,P=0.02)。地西他滨治疗后 SLC19A1 甲基化略有减少(统计学上无显著性),并且 SLC19A1 甲基化随地西他滨的变化与 LINE1 甲基化的变化呈趋势相关(r=0.47,P<0.15)。虽然 SLC19A1 甲基化与 RFC1 评分无关,但 SLC19A1 甲基化的变化与 RFC1 表达的变化之间存在趋势呈负相关(r=-0.45,P=0.19)。

结论

总之,地西他滨给药后,一些(但不是其他)转运蛋白的表达增加,这些转运蛋白可能在化疗摄取中起作用。需要更多的患者数量来确定这种表达增加与 DNA 甲基化变化的关联程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2be3/3895853/7243b4f63af9/1868-7083-6-2-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验